Redifferentiation Therapy in Thyroid Cancer

Abstract

Thyroid cancer originates from epithelial and from parafollicular C-cells. Distant metastases occur in about 5–10 % of patients. RAI therapy and TSH suppressive therapy have an established role in the management of disseminated thyroid cancer, yet in most of these patients disease progress is only a matter of time. Disease progression is usually accompanied by dedifferentiation of cancer cells and standard therapies are no more effective. In this chapter new molecular backgrounds and clinical data on novel redifferentiating agents are discussed.